This study examines the shift from treat-to-target to early highly effective treatment (EHT) approaches in managing multiple sclerosis in Germany. Using pharmacy data from 2020 to 2022, it found an increasing preference for EHT, marked by a rise in high-efficacy medication prescriptions. This trend reflects a growing acceptance of EHT among healthcare providers despite existing guidelines.
Steffeni Papukchieva, Ann-Sophie Stratil, Maria Kahn, Nils-Henning Neß, Maike Hollnagel Schmitz, Vivien Gerencser, Julia Rustemeier, Markus Eberl, Benjamin Friedrich, and Tjalf Ziemssen (2024). Shifting from treat-to-target to the early highly effective treatment approach in patients with multiple sclerosis - real-world evidence from Germany. Sage Journal, Therapeutic Advances in Neurological DisordersVolume 17, 2024
